These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12975936)

  • 21. [Is lupus erythematosus a type of toxicoderma or an inflammation; synthetic antimalarials seen as antiphologistic therapy].
    JUSTER E
    Bull Soc Fr Dermatol Syphiligr; 1955; (5):505-7. PubMed ID: 13316367
    [No Abstract]   [Full Text] [Related]  

  • 22. [Is lupus erythematosus a toxicoderma? (from antipyrine to hydralazine)].
    GRUPPER C
    Bull Soc Fr Dermatol Syphiligr; 1955; (3):336-8. PubMed ID: 13270062
    [No Abstract]   [Full Text] [Related]  

  • 23. [Observations on L. E. phenomenon. I. The L. E. phenomenon in clinical varieties of lupus erythematosus].
    RASPONI L
    Arch Ital Dermatol Sifilogr Venereol; 1954; 26(2):121-40. PubMed ID: 13198527
    [No Abstract]   [Full Text] [Related]  

  • 24. A peculiar form of amicrobial pustulosis of the folds associated with systemic lupus erythematosus and other auto-immune diseases.
    Lagrange S; Chosidow O; Piette JC; Wechsler B; Godeau P; Frances C
    Lupus; 1997; 6(6):514-20. PubMed ID: 9256309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lupus erythematosus; the effect of cortisone on the "L. E." phenomenon in lupus erythematosus.
    MacDONALD GR; SIMMONS NW
    Can Med Assoc J; 1950 Nov; 63(5):477-8. PubMed ID: 14778099
    [No Abstract]   [Full Text] [Related]  

  • 26. CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.
    Favoino E; Prete M; Marzullo A; Millo E; Shoenfeld Y; Perosa F
    Clin Rev Allergy Immunol; 2017 Apr; 52(2):217-233. PubMed ID: 27216429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Symposium on immunologic disorders and their control.
    Jpn J Med; 1982 Jan; 21(1):56-70. PubMed ID: 6461791
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical immune complex disease. Manifestations in systemic lupus erythematosus and hepatitis B virus infection.
    Kohler PF
    Medicine (Baltimore); 1973 Sep; 52(5):419-29. PubMed ID: 4125355
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pathophysiological implications of antigen-antibody complexes (author's transl)].
    Zubler R; Nydegger UE; Izui S; Lambert PH; Miescher PA
    Pathol Microbiol (Basel); 1975; 42(4):287-94. PubMed ID: 132628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus.
    Verma J; Arora V; Marwaha V; Kumar A; Das N
    Lupus; 2005; 14(4):273-9. PubMed ID: 15864913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical and molecular abnormalities in the pathogenesis of systemic lupus erythematosus.
    Tsokos GC
    Clin Exp Rheumatol; 1991; 9(5):533-9. PubMed ID: 1954706
    [No Abstract]   [Full Text] [Related]  

  • 32. [Neuropsychiatric and vascular manifestations of disseminated lupus erythematosus].
    Correia Jde A; Ramada JA; Rocha RN; Bernardo JM
    Acta Med Port; 1991; 4(3):160-1. PubMed ID: 1950668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythrophagocytosis in vitro. I. Specificity and sensitivity.
    Lee CL; Zandrew F; Gernand L; Davidsohn I
    Vox Sang; 1968; 15(3):203-8. PubMed ID: 4176319
    [No Abstract]   [Full Text] [Related]  

  • 34. [Lupus erythematosus phenomenon and other auto-phagocytosis phenomena in blood. Frequency and diagnostic significance. LE cells, nucleophagocytoses, leukophagocytoses, erythrophagocytoses].
    BEICKERT A; GEIDEL H
    Dtsch Med Wochenschr; 1960 Oct; 85():1846-56. PubMed ID: 13688726
    [No Abstract]   [Full Text] [Related]  

  • 35. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus.
    Jones SA; Toh AE; Odobasic D; Oudin MA; Cheng Q; Lee JP; White SJ; Russ BE; Infantino S; Light A; Tarlinton DM; Harris J; Morand EF
    Ann Rheum Dis; 2016 Apr; 75(4):739-47. PubMed ID: 26612340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current concepts on the pathogenesis of lupus nephritis].
    Tareeva IE
    Arkh Patol; 1973; 35(6):74-82. PubMed ID: 4361708
    [No Abstract]   [Full Text] [Related]  

  • 37. [Interpretation of the L. E. phenomenon].
    VACCAREZZA AJ
    Rev Asoc Med Argent; 1953; 67(755-758):330-1. PubMed ID: 13134682
    [No Abstract]   [Full Text] [Related]  

  • 38. Studies on the mechanism of the lupus erythematosus (L.E.) phenomenon.
    AISENBERG AC
    J Clin Invest; 1959 Feb; 38(2):325-33. PubMed ID: 13631063
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-induced lupus.
    Rubin RL
    Expert Opin Drug Saf; 2015 Mar; 14(3):361-78. PubMed ID: 25554102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus.
    Liao TD; Nakagawa P; Janic B; D'Ambrosio M; Worou ME; Peterson EL; Rhaleb NE; Yang XP; Carretero OA
    Am J Physiol Renal Physiol; 2015 May; 308(10):F1146-54. PubMed ID: 25740596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.